• 1
    Emmerson BT. The management of gout. N Engl J Med 1996; 334: 44551.
  • 2
    Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 131224.
  • 3
    Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999; 59: 92534.
  • 4
    Hershfield MS. Gout and uric acid metabolism. In: GoldmanL, BennettJC, editors. Cecil textbook of medicine. 21st ed. Philadelphia: WB Saunders; 2000. p. 15418.
  • 5
    Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 57780.
  • 6
    Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15: 18992.
  • 7
    Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007; 19: 1227.
  • 8
    Terkeltaub RA. Clinical practice: gout. N Engl J Med 2003; 349: 164755.
  • 9
    Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005; 17: 31924.
  • 10
    Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 245061.
  • 11
    Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12: 615.
  • 12
    Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 3215.
  • 13
    Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 138.
  • 14
    Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 35660.
  • 15
    Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005; 52: 91623.
  • 16
    Choy G. An update on the treatment options for gout and calcium pyrophosphate deposition. Expert Opin Pharmacother 2005; 6: 244353.
  • 17
    Keith MP, Gilliland WR. Updates in the management of gout. Am J Med 2007; 120: 2214.
  • 18
    Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27: 33743.
  • 19
    Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 4756.
  • 20
    Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 827.
  • 21
    Allopurinol tablets, USP [package insert]. Spring Valley (NY): Par Pharmaceutical; 2001.
  • 22
    Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics [abstract]. Arthritis Res Ther 2006; 8 Suppl 1: S4.
  • 23
    Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003; 278: 184855.
  • 24
    Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005; 76: 183547.
  • 25
    Yamamoto T, Moriwaki Y, Fujimura Y, Takahashi S, Tsutsumi Z, Tsutsui T, et al. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology 2000; 60: 3440.
  • 26
    Grabowski BA, Vernillet L, Khosravan R, Wu J, Joseph-Ridge N, Mulford DJ. Absorption, metabolism and excretion of [14C]febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in healthy male subjects [abstract]. Drug Metab Rev 2005; 37: 111.
  • 27
    Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004; 23: 11116.
  • 28
    Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 2006; 45: 82141.
  • 29
    Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004; 23: 111922.
  • 30
    Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004; 23: 11178.
  • 31
    Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005; 12: 2234.
  • 32
    Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895900.
  • 33
    Schumacher HR, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005; 32: 236872.
  • 34
    Hochberg Y. A sharper Bonferroni procedure for multiple test of significance. Biometrika 1988; 75: 8002.
  • 35
    Brewis I, Ellis RM, Scott JT. Single daily dose of allopurinol. Ann Rheum Dis 1975; 34: 2569.
  • 36
    Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 5459.
  • 37
    Rodnan GP, Robin JA, Tolchin SF, Elion GB. Allopurinol and gouty hyperuricemia: efficacy of a single daily dose. JAMA 1975; 231: 11437.
  • 38
    Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 22958.
  • 39
    Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33: 164650.
  • 40
    Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60: 9813.
  • 41
    Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology (Oxford) 2006; 45: 142231.